Latest news with #VerveTherapeutics
Yahoo
2 days ago
- Business
- Yahoo
Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102
Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the . On April 14, Verve Therapeutics, Inc. (NASDAQ:VERV) reported results from its Heart-2 Phase 1b trial for VERVE-102. The trial focused on treating people with heterozygous familial hypercholesterolemia or early heart disease. Such patients need to lower their LDL cholesterol levels for a long time. Management noted that 14 participants received VERVE-102 at different doses, and the treatment was marked safe as there were no serious side effects connected to the drug and no important lab problems were seen. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting. The results showed that a single infusion of VERVE-102 reduced a key blood protein and significantly dropped LDL cholesterol. The reduction was dependent on the dose, with a mean reduction of 53% and a maximum reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort. Management believes that these results are promising, as a single dose can offer long-lasting reduction in LDL cholesterol. Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company developing genetic medicines for cardiovascular disease. Their treatments aim to provide long-lasting effects with a single gene-editing therapy instead of ongoing medication. While we acknowledge the potential of VERV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 days ago
- Business
- Yahoo
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease." About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-07-2025
- Business
- Yahoo
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.
Forbes
08-07-2025
- Business
- Forbes
Healthcare ETF Underperforms S&P 500: Price Charts Show How Much
Healthcare stocks The big healthcare stocks are not keeping up with wider stock market. When the S&P 500 and the Nasdaq 100 recently popped to new highs, this sector vastly underperformed it. It's likely the problem has to do with much investor concern about cuts to Medicaid and other 'big beautiful bill' adjustments. 4 Healthcare Stocks (And The ETF) Fail To Keep Up Healthcare Select Sector SPDR ETF: Healthcare Select Sector SPDR ETF, daily price chart, 7 7 25. The fund is way down from those October 2024 prices. The rally from mid-December 2024 to early March 2025 failed to make it above the previous autumn's highs. The 200-day moving average is trending downward. Note that the 50-day moving average crossed below the 200-day in mid-December 2024. The ETF has 60 holdings in the sector. Eli Lilly. Eli Lilly daily price chart, 7 7 25. One of the old-school brand names in the group, Eli Lilly has been in business for 150 years. The drug maker focuses on cancer, immunology, diabetes and obesity, among other areas. The company recently acquired Verve Therapeutics, a Boston firm working on cardiovascular treatments. The stock hit a peak in February of just above $930. It joined others dropping into April 7 where the price bottomed at near $675. A brief rally from there failed to close above a declining 200-day moving average and now Lilly trades under the 50-day moving average. Market cap is $732.48 billion. Johnson & Johnson Johnson & Johnson daily price chart, 7 7 25. With a market cap of $373.59 billion, the company is component of the Dow Jones Industrial Average and of the S&P 500. Johnson & Johnson is a household name: it's been around for 139 years. The price-earnings ratio is 17. The drug maker pays a dividend of 3.31%. The stock reached a peak in early March of $168. It's been unable to recover to anywhere near that level following the early April sell-off. Today's closing price puts it above both the 50-day and the 200-day moving averages. Abbvie AbbVie daily price chart, 7 7 25. The North Chicago-based drug manufacturer recently purchased biotech firm Capstan for $2.1 billion. In May, Citigroup downgraded their opinion of AbbVie from 'buy" to 'neutral' with a price target of $205. In April, Cantor Fitzgerald initiated coverage with an 'overweight' tag, price targeted for $210. AbbVie pays a 3.47% dividend. The price peaked in early March at near $216. The sell-off into early April was dramatic with a price drop to near $162.50. Today's close put it at just above the 50-day moving average and the 200-day moving average. Amgen Amgen daily price chart, 7 7 25. Amgen hit a peak of just above $330 in early March. The stock tanked in early April along with the market as a whole but never made it back to the high. Right now, the price is slightly above a down-trending 200-day moving average. Friday's high could not quite make it above the June high near $300. The drug manufacturer has a market cap of $157.52 billion. The Thousand Oaks, California-based company is a component of the Dow Jones Industrial Average, the S&P 500 and the Nasdaq 100. The stock trades with a price-earnings ratio of 26. Amgen pays a 3.29% dividend. Stats courtesy of Charts courtesy of No artificial intelligence was used in the writing of this post. More analysis and commentary at
Yahoo
23-06-2025
- Business
- Yahoo
Lilly To Acquire Verve For One-Time Cardiovascular Treatments
Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc. (NASDAQ:VERV)'s 30-day average share price as of June 16, 2025. Single-dose gene-editing therapies for atherosclerotic cardiovascular disease are being developed by Verve Therapeutics, Inc. (NASDAQ:VERV), including their flagship program VERVE-102, which targets PCSK9. The medication, which is currently in Phase 1b and has been granted FDA Fast Track designation, has the potential to transform care for patients suffering from heterozygous familial hypercholesterolemia and early coronary artery disease. According to Lilly, Verve Therapeutics, Inc. (NASDAQ:VERV)'s platform strengthens its cardiometabolic pipeline. Sekar Kathiresan, CEO of Verve, stressed the company's goal of moving from chronic to one-time care. Insiders of the firm who own 17.8% of the company have decided to tender. While we acknowledge the potential of VERV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
